<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Introduction</h3>
<p>Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes. Current clinical practice reduces the risk of bleeds, making differences difficult to measure. We surveyed specialist haemophilia nurses to discern their opinions about the impact of haemophilia B compared to haemophilia A.</p>
</sec>
<sec><h3>Methods</h3>
<p>Between July and September 2020, European and Canadian nurses were invited to complete an online survey (25 questions) about perceptions of management and treatment of haemophilia B.</p>
</sec>
<sec><h3>Results</h3>
<p>Fifty-nine nurses (46 European, 13 Canadian) completed the survey. Bleeding was reported as different in haemophilia B by 37% of respondents, and treatment as different by over half. Opinions and experience around using extended half-life (EHL) products varied. Self-reported confidence in using EHL products was rated at a mean of 7.1 (range 3–10) with 47% believing these would remain the optimal treatment in 2025.</p>
</sec>
<sec><h3>Conclusion</h3>
<p>Some nurses believe haemophilia A and B are managed differently. Variations in experience and levels of confidence in the use of EHL products, combined with a belief that these products will remain an optimal treatment for haemophilia B for the next five years, indicates a need for education to promote confidence and competence.</p>
</sec>
</abstract>

Introduction
Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes. Current clinical practice reduces the risk of bleeds, making differences difficult to measure. We surveyed specialist haemophilia nurses to discern their opinions about the impact of haemophilia B compared to haemophilia A.

Methods
Between July and September 2020, European and Canadian nurses were invited to complete an online survey (25 questions) about perceptions of management and treatment of haemophilia B.

Results
Fifty-nine nurses (46 European, 13 Canadian) completed the survey. Bleeding was reported as different in haemophilia B by 37% of respondents, and treatment as different by over half. Opinions and experience around using extended half-life (EHL) products varied. Self-reported confidence in using EHL products was rated at a mean of 7.1 (range 3–10) with 47% believing these would remain the optimal treatment in 2025.

Conclusion
Some nurses believe haemophilia A and B are managed differently. Variations in experience and levels of confidence in the use of EHL products, combined with a belief that these products will remain an optimal treatment for haemophilia B for the next five years, indicates a need for education to promote confidence and competence.

Haemophilia specialist nurses’ perceptions of haemophilia B

Coagulation Centre, Department of Medicine/Section of Hematology and Coagulation

Division of Internal Medicine and Dermatology

Van Creveldkliniek University Medical Center Utrecht

The Journal of Haemophilia Practice

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Haemophilia specialist nurses\u2019 perceptions of haemophilia B"}

Introduction
Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in...

PRODUCT		N	%
Standard half-life
Nonacog alfa	Benefix ^[31]	47	80%
Nonacog gamma	Rixubis ^[32]	11	19%
Extended half-life
Albutrepenonacog alfa	Idelvion ^[9]	22	37%
Eftrenonacog alfa	Alprolix ^[8]	36	61%
Nonacog beta pegol	Refixia/Rebinyn ^[10]	13	22%
Other		17	29%

Haemophilia specialist nurses’ perceptions of haemophilia B

Article Category: Clinical Practice

Publié en ligne: 14 oct. 2021

Pages: 119 - 127

DOI: https://doi.org/10.2478/jhp-2021-0013

Mots clés
Haemophilia B, specialist nurses, factor IX, long-acting clotting factor, EHL FIX

© 2021 Steve Chaplin et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Experience of use of factor IX products

Haemophilia specialist nurses’ perceptions of haemophilia B

Article Category: Clinical Practice

Publié en ligne: 14 oct. 2021

Pages: 119 - 127

DOI: https://doi.org/10.2478/jhp-2021-0013

Mots clésHaemophilia B, specialist nurses, factor IX, long-acting clotting factor, EHL FIX

© 2021 Steve Chaplin et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Figure 2

Experience of use of factor IX products

Mots clés
Haemophilia B, specialist nurses, factor IX, long-acting clotting factor, EHL FIX